Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$8.4M
Filings
64
Firms Hired
2
Active Period
2014–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
2026 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 9260 - LHHS Appropriations
Client expense: $160,000 · Firm income: —
Matched citations: H.R. 9260
Accelerating Kids’ Access to Care Act of 2025
2026 · second_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 1509
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
2026 · second_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 9260 - LHHS Appropriations
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 9260
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Client expense: $180,000 · Firm income: —
Matched citations: H.R.2617
Protecting Health Care for All Patients Act of 2022
2022 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Client expense: $180,000 · Firm income: —
Matched citations: H.R.7634
Orphan Drug COVID–19 Mitigation Act of 2022
2022 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Client expense: $180,000 · Firm income: —
Matched citations: H.R.8641
Newborn Screening Saves Lives Reauthorization Act of 2021
2022 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Client expense: $180,000 · Firm income: —
Matched citations: S.350
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Client expense: $230,000 · Firm income: —
Matched citations: H.R.5376
Protecting Health Care for All Patients Act of 2022
2022 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Client expense: $230,000 · Firm income: —
Matched citations: H.R.7634
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Client expense: $230,000 · Firm income: —
Matched citations: H.R.7667
Newborn Screening Saves Lives Reauthorization Act of 2021
2022 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Client expense: $230,000 · Firm income: —
Matched citations: S.350
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Client expense: $230,000 · Firm income: —
Matched citations: S.4348
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Client expense: $120,000 · Firm income: —
Matched citations: H.R.7389
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Client expense: $120,000 · Firm income: —
Matched citations: H.R.7667
American Data Privacy and Protection Act
2022 · second_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Client expense: $120,000 · Firm income: —
Matched citations: H.R.8152
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Client expense: $120,000 · Firm income: —
Matched citations: S.4348
Consolidated Appropriations Act, 2022
2022 · first_quarter · Firm: CORNERSTONE GOVERNMENT AFFAIRS, INC.
FY 222 Appropriations Bill HR 2471
Client expense: — · Firm income: $10,000
Matched citations: HR 2471
Accelerated Approval Integrity Act of 2022
2022 · first_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.6963 - Accelerated Approval Integrity Act of 2022; All Provisions
Client expense: $100,000 · Firm income: —
Matched citations: H.R.6963
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
2021 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Matters related to Gene Therapy funding
Client expense: $140,000 · Firm income: —
Matched citations: H.R.4356
The Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · first_quarter · Firm: SAREPTA THERAPEUTICS, INC.
S.2158 - Newborn Screening Saves Lives Reauthorization Act of 2019
Client expense: $140,000 · Firm income: —
Matched citations: S.2158
Newborn Screening Saves Lives Reauthorization Act of 2019
2019 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
Client expense: $150,000 · Firm income: —
Matched citations: H.R. 2507
Prescription Drug Pricing Reduction Act of 2019
2019 · fourth_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
Client expense: $150,000 · Firm income: —
Matched citations: S.2543
Newborn Screening Saves Lives Reauthorization Act of 2019
2019 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Client expense: $150,000 · Firm income: —
Matched citations: H.R.2507
The Newborn Screening Saves Lives Reauthorization Act of 2019
2019 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Client expense: $150,000 · Firm income: —
Matched citations: S. 2158
Newborn Screening Saves Lives Reauthorization Act of 2019
2019 · third_quarter · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Client expense: $150,000 · Firm income: —
Matched citations: H.R.2507
Source: Senate LDA